LUXEMBOURG – In a significant move to fortify the resilience of Lebanon’s beleaguered healthcare sector, the World Health Organization (WHO) and the European Investment Bank (EIB Global) have formalized a strategic partnership. On 6 March 2025, during the EIB Group Forum in Luxembourg, WHO Director-General Dr. Tedros Adhanom Ghebreyesus and EIB Vice-President Thomas Östros signed a landmark agreement providing a €10 million grant aimed at stabilizing public health services in the Mediterranean nation.
This collaboration marks a pivotal moment for Lebanon, a country currently navigating an unprecedented intersection of economic collapse, regional instability, and a strained medical infrastructure. The infusion of capital is designed not merely as a temporary relief measure, but as a foundational investment in sustainable health security.
The Core Mandate: Rebuilding Foundations
The primary objective of this €10 million initiative is twofold: the restoration of critical laboratory infrastructure and the immediate procurement of essential life-saving medications.
The Central Public Health Laboratory (CPHL)
The centerpiece of the agreement is the re-establishment of Lebanon’s Central Public Health Laboratory. In any functional health system, a national public health laboratory acts as the "eyes and ears" of the medical community. It is the facility responsible for disease surveillance, diagnostic testing for communicable diseases, and ensuring the safety of the food and water supply.
In recent years, the CPHL has suffered from severe neglect due to budgetary constraints and the broader economic crisis. By prioritizing its rehabilitation, the WHO and EIB are providing Lebanon with the diagnostic capability necessary to detect, monitor, and respond to potential epidemics. This facility will serve as the backbone for national health security, ensuring that policymakers have the data-driven insights required to manage public health crises effectively.
Bridging the Gap in Chronic Care
Beyond infrastructure, the grant addresses a dire humanitarian concern: the accessibility of medication. Lebanon has seen its healthcare system pushed to the brink, with many patients suffering from chronic conditions unable to secure consistent treatment due to the devaluation of the local currency and supply chain disruptions.
The initiative aims to provide direct healthcare support to over 50,000 individuals suffering from chronic diseases, including diabetes, cardiovascular disorders, and various forms of cancer. By streamlining the supply chain and ensuring the availability of these essential medicines, the project seeks to prevent a secondary wave of mortality—deaths caused not by conflict, but by the systemic inability to treat manageable chronic conditions.
A Chronology of Crisis and Intervention
The necessity of this partnership is best understood through the timeline of the broader crisis in Lebanon.
- 2019–2021: The Economic Descent: Lebanon entered a deep financial crisis characterized by hyperinflation, which effectively wiped out the purchasing power of the Ministry of Public Health. Medical imports plummeted, and health professionals began a mass exodus, creating a "brain drain" that weakened the sector.
- 2022–2023: The Strain on Public Services: As the economic situation deteriorated, the burden on public hospitals increased. The reliance on NGOs grew, but the lack of a centralized, robust laboratory system hampered the ability of authorities to manage health outcomes.
- 2024: Negotiating the Partnership: Throughout 2024, the WHO and EIB engaged in high-level discussions to identify where international funding could have the most profound impact. It was determined that a "systems-level" approach—fixing the lab and securing long-term drug supplies—was more sustainable than ad-hoc emergency aid.
- 6 March 2025: Formalization in Luxembourg: At the EIB Group Forum, the €10 million agreement was officially signed, transitioning the project from planning to implementation.
Supporting Data: The Case for Intervention
The urgency of this intervention is supported by sobering statistics regarding the state of health in Lebanon. According to recent WHO assessments, the cost of medical care in Lebanon has risen by over 1,000% since 2019, making essential treatment for non-communicable diseases (NCDs) unattainable for the average citizen.
- Chronic Disease Burden: Over 30% of the Lebanese population is estimated to suffer from at least one chronic condition. In a pre-crisis environment, these were managed through subsidized public clinics; today, the supply of subsidized insulin, antihypertensives, and oncology treatments is sporadic at best.
- Diagnostic Deficits: Prior to this initiative, the absence of a fully operational Central Public Health Laboratory meant that Lebanon was forced to rely on fragmented, often private, testing facilities. This lack of centralized surveillance created "blind spots" in the national health picture, particularly concerning waterborne diseases and emerging infectious threats.
- Demographic Reach: The target of 50,000 patients is a strategic starting point. By focusing on the most vulnerable demographics—the elderly and those in rural areas—the program aims to reduce the burden on tertiary care hospitals, which are currently overwhelmed.
Official Responses: Aligning Global Priorities
The partnership reflects a growing trend in international development: the alignment of financial institutions (EIB) with health agencies (WHO) to address the "Health-Economy Nexus."
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General:
During the signing, Dr. Tedros emphasized the critical nature of the partnership. "Health is a human right, not a luxury reserved for times of economic stability. This agreement with the EIB is a vital lifeline for the people of Lebanon. By restoring the Central Public Health Laboratory, we are not just fixing a building; we are restoring the nation’s ability to protect its own people from disease. We remain committed to ensuring that those living with chronic diseases do not have to choose between their health and their survival."
Thomas Östros, EIB Vice-President:
Mr. Östros highlighted the role of the EIB in fostering regional stability through infrastructure. "At the EIB, we recognize that economic growth cannot exist without a healthy population. By supporting this initiative, we are leveraging our financial expertise to help Lebanon maintain its public health integrity during these challenging times. This grant is part of our broader commitment to supporting the social and economic resilience of the Mediterranean region."
The Broader Implications: What This Means for Lebanon
The implications of this €10 million grant extend far beyond the immediate procurement of drugs and the renovation of a lab.
Strengthening Institutional Trust
One of the most significant casualties of the Lebanese crisis has been the public’s trust in state institutions. When citizens feel that their government cannot provide basic medicine or conduct reliable diagnostic testing, the social contract fractures. By reviving the Central Public Health Laboratory under the aegis of the Ministry of Public Health, the WHO and EIB are helping the Lebanese government reassert its role as the primary provider of health security.
Sustainability and Regional Security
The regional dimension cannot be overlooked. Lebanon hosts a significant number of refugees, and the strain on its health system has regional implications for disease control. A robust health surveillance system in Lebanon serves as a protective buffer for the entire Levant region. By preventing outbreaks and managing chronic conditions, the project lowers the risk of regional health instability.
A Model for Future Cooperation
This project serves as a pilot for how international financial institutions (IFIs) can partner with specialized UN agencies. Traditionally, WHO focuses on technical guidance and policy, while the EIB focuses on infrastructure financing. This marriage of competencies—technical expertise paired with long-term capital—provides a blueprint for other nations facing "polycrisis" scenarios.
Moving Toward Universal Health Coverage (UHC)
Ultimately, the goal of this initiative is to keep the dream of Universal Health Coverage alive in Lebanon. While the current climate makes full UHC difficult, the partnership provides a bridge, ensuring that the health system does not collapse entirely. By maintaining the supply of essential medicines, the initiative buys time for the Lebanese government to undertake the structural reforms necessary to stabilize the economy and, eventually, the health sector.
Conclusion: A Step Toward Resilience
The €10 million grant signed in Luxembourg is more than just a financial transaction; it is a declaration of commitment to the people of Lebanon. As the nation grapples with its complex realities, the restoration of the Central Public Health Laboratory and the provision of life-saving medicines provide a tangible path toward recovery.
While the challenges ahead remain substantial, this partnership between the WHO and EIB Global ensures that the fundamental rights of the Lebanese people—specifically the right to health—remain at the forefront of the international agenda. Through careful implementation, transparent management, and continued international oversight, this initiative has the potential to serve as a beacon of progress in a region that has known too much instability.
As the project enters its operational phase, the international community will be watching closely, hoping that this investment will yield not only better health outcomes but also the institutional strength required for Lebanon’s long-term prosperity.
About the Author
